Xeris Pharmaceuticals Inc.

NASDAQ: XERSHealthcare / Biotechnology / USA
12.19+0.5700+4.91%Vol 339 7911Y Perf -50.46%
Aug 21st, 2019 16:00
BID12.19 ASK12.22
Open11.65 Previous Close11.62
Pre-Market- After-Trading-
 - -%  - -%
Target Price
20.00 
Analyst Rating
Strong Buy 1.00
Potencial %
64.07 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/-41 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/48/-70 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/50/-56 
Income Ranking
 —    -
Market Cap (mil)329 
Earnings Rating
Strong Sell
Price Range Ratio 52wk %
25.27 
Earnings Date
12th Aug 2019

Today's Price Range

11.6212.50

52wk Range

6.8527.98

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
12.77%
1 Month
-4.77%
3 Months
-2.40%
6 Months
23.76%
1 Year
-50.46%
3 Years
-
5 Years
-
10 Years
-

Name / TickerPriceChg.Chg.%
XERS12.190.57004.91
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.97-1.28-31.96
Q01 2019-0.83-1.07-28.92
Q04 2018-1.04-0.985.77
Q03 2018-0.84-0.7115.48
Q02 2018-0.87-3.07-252.87
----
----
----
Earnings Per EndEstimateRevision %Trend
9/2019 QR-1.24-39.33Negative
12/2019 QR-1.13-32.94Negative
12/2019 FY-4.72-37.61Negative
12/2020 FY-3.24-31.71Negative
Next Report Date-
Estimated EPS Next Report-0.97
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume339 791
Shares Outstanding (in ths.)26 987
Trades Count652
Dollar Volume1 219 468
Avg. Volume212 530
Avg. Weekly Volume158 870
Avg. Monthly Volume153 193
Avg. Quarterly Volume196 507
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.25
Strong Buy
1.25

Xeris Pharmaceuticals Inc.

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, Continuous Glucagon, and others.

CEO: Paul R. Edick

Teplephone: +1 844 445-5704

Address: 180 North LaSalle Street, Chicago 60601, IL, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

60%40%

Bearish Bullish

44%56%

News